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Background: Beta-lactam resistance in Haemophilus influenzae due to ftsI mutations causing altered
penicillin-binding protein 3 (PBP3) is increasing worldwide. Low-level resistant isolates with the N526K
substitution (group II low-rPBP3) predominate in most geographical regions, while high-level resistant isolates
with the additional S385T substitution (group III high-rPBP3) are common in Japan and South Korea.
Knowledge about the molecular epidemiology of rPBP3 strains is limited. We combined multilocus sequence
typing (MLST) and ftsI/PBP3 typing to study the emergence and spread of rPBP3 in nontypeable H. influenzae
(NTHi) in Norway.
Results: The prevalence of rPBP3 in a population of 795 eye, ear and respiratory isolates (99% NTHi) from 2007
was 15%. The prevalence of clinical PBP3-mediated resistance to ampicillin was 9%, compared to 2.5% three
years earlier. Group II low-rPBP3 predominated (96%), with significant proportions of isolates non-susceptible to
cefotaxime (6%) and meropenem (20%). Group III high-rPBP3 was identified for the first time in Northern Europe.
Four MLST sequence types (ST) with characteristic, highly diverging ftsI alleles accounted for 61% of the rPBP3
isolates. The most prevalent substitution pattern (PBP3 type A) was present in 41% of rPBP3 isolates, mainly
carried by ST367 and ST14. Several unrelated STs possessed identical copies of the ftsI allele encoding PBP3 type A.
Infection sites, age groups, hospitalization rates and rPBP3 frequencies differed between STs and phylogenetic
groups.
Conclusions: This study is the first to link ftsI alleles to STs in H. influenzae. The results indicate that horizontal
gene transfer contributes to the emergence of rPBP3 by phylogeny restricted transformation.
Clonally related virulent rPBP3 strains are widely disseminated and high-level resistant isolates emerge in new
geographical regions, threatening current empiric antibiotic treatment. The need of continuous monitoring of
beta-lactam susceptibility and a global system for molecular surveillance of rPBP3 strains is underlined.
Combining MLST and ftsI/PBP3 typing is a powerful tool for this purpose.
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Haemophilus influenzae is a major cause of respiratory
tract infections and invasive disease, with encapsulated
strains of serotype b (Hib) being most virulent [1]. Non-
typeable isolates (NTHi) now account for the majority of
cases of invasive disease in countries where Hib conju-
gate vaccines have been introduced [2-4]. NTHi vaccines
have a huge potential for further reducing the global
burden of disease but are not yet available [1,5].
Beta-lactams are first-line drugs for treatment of
H. influenzae infections but resistance may develop due
to transferable beta-lactamases (impacting penicillins only)
or alterations in the transpeptidase domain of penicillin-
binding protein 3 (PBP3), encoded by the ftsI gene (impact-
ing all beta-lactams) [6]. Traditionally, isolates with the
latter resistance mechanism have been denoted beta-lacta-
mase negative ampicillin resistant (BLNAR), whereas
isolates with both mechanisms have been denoted
beta-lactamase positive amoxicillin-clavulanate resistant
(BLPACR). PBP3-mediated resistance is defined by the
presence of particular amino acid substitutions (Table 1):
R517H or N526K near the KTG motif in low-level re-
sistant isolates (groups I and II, respectively), and the
additional substitution S385T near the SSN motif in high-
level resistant isolates (group III-like, S385T + R517H;
group III, S385T + N526K) [7-10].
An increased prevalence of PBP3-mediated resistance
(hereafter denoted rPBP3) has been observed worldwide
[2,4,11-16]. Isolates with high-level resistance (high-rPBP3)
are a major clinical problem in Japan and South Korea
[15-17] whereas low-level resistant (low-rPBP3) isolates so
far predominate in the rest of the world [4,11,12,14,18-21].Table 1 Genotypes of PBP3-mediated resistance in
Haemophilus influenzae
Genotype designationsa PBP3 substitutionsb
SSN KTG
Categoryc Level Group S385 R517 N526
rPBP3 High IIId T K
III-likee T H
Low II K
I H
sPBP3 NA NA
aAccording to Ubukata et al. [7], Hasegawa et al. [8], Garcia-Cobos et al. [9],
Hotomi et al. [10] and this study. NA, not applicable.
bEssential amino acid substitutions in PBP3 (transpeptidase domain, 338–573)
with the amino acid sequence of H. influenzae Rd KW20 [GenBank:U32793] as
reference. SSN, Ser-Ser-Asn motif; KTG, Lys-Thr-Gly motif.
crPBP3, isolates with PBP3 sequences conferring resistance to beta-lactams
(isolates assigned to groups I, II, III-like and III); sPBP3, isolates with PBP3
sequences conferring wild-type susceptibility to beta-lactams
(remaining isolates).
dOriginally reserved for isolates with the additional substitutions M377I and
L389F by Ubukata et al. [7], modification proposed by Hotomi et al. [10].
eOriginally categorized as group I by Ubukata et al. [7], new group assignment
proposed by Garcia-Cobos et al. [9].Group II isolates with a characteristic substitution pattern,
PBP3 type A (D350N, M377I, A502V, N526K, V547I and
N569S) [11], and compatible patterns (identical to PBP3
type A as far as comparison is possible) are particularly
common [3,4,9,11,12,16,18,20,22-25]. The mechanisms by
which rPBP3 isolates emerge are not fully understood.
Spontaneous mutations are considered the primary cause
of the substitutions R517H, N526K and S385T [6,26] but
horizontal gene transfer (HGT) by classical transformation
and homologous recombination has been suggested to play
an important role in the further development and spread
of resistance [11,26-28].
Clonal spread of rPBP3-NTHi is extensively docu-
mented [3,4,6,9-11,18,26]. However, knowledge about the
molecular epidemiology of rPBP3 strains is limited. Pre-
vious studies based on pulsed-field gel electrophoresis
(PFGE) and other molecular methods have generated
results not easily compared between studies. Multilocus
sequence typing (MLST) has the advantage of providing
objective, unambiguous data, easy to compare and well
suited for assessment of phylogenetic relationship in both
encapsulated isolates and NTHi [29,30]. The MLST
scheme for H. influenzae assigns isolates to sequence
types (ST) based on allelic profiles of the seven house-
keeping genes adk, atpG, frdB, fucK, mdh, pgi and recA
[30]. Software for phylogenetic analysis and a continuously
updated database with STs, serotypes and clinical data
(but not resistance genotypes) is available on the website
http://haemophilus.mlst.net. MLST has improved our
understanding of population structure in H. influenzae
[29-32]. A maximum-parsimony analysis of concatenated
sequences from all isolates in the database has identified 14
phylogenetic groups (Clades 1–13 and eBURST group 2)
with different genetic characteristics, including serotypes
and virulence determinants [32].
The objectives of this study were to: 1) Estimate the
prevalence of rPBP3 in eye, ear and respiratory isolates
of H. influenzae in Norway and map PBP3 genotypes
and phenotypic beta-lactam susceptibility profiles; 2)
Examine the molecular epidemiology of rPBP3 isolates
and seek for evidence of HGT; and 3) Explore any asso-
ciations between phylogeny, resistance genotypes and
pathogenicity, as reflected by clinical characteristics (age,
gender, hospitalization rates and sample types).
Methods
Bacterial isolates
One hundred and seventy-seven H. influenzae isolates
with a phenotype suggesting rPBP3 (Resistant group,
R-group) and 19 isolates with wild-type susceptibility
to beta-lactams (Susceptible group, S-group) were charac-
terized. The isolates were selected from a population of
808 consecutive eye, ear and respiratory tract isolates,
collected as part of standard patient care in January and
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Programme for Antimicrobial Resistance (NORM) [33].
Selection was based on the susceptibility profiles reported
by the primary laboratories (Figure 1). Thirteen isolates
were selected but excluded for various reasons. Clinical
information (site of isolation; age and gender of the
patient; hospitalization status at the time of sampling)
for the 196 study isolates and 599 isolates in the original
population was used for statistical analyses.
PFGE band patterns and ftsI sequences for 46H. influ-
enzae isolates from a comparable population collected in
2004, characterized in a previous study [11], were included
in the phylogenetic analyses.
Species identification and serotyping
Isolates were inoculated on chocolate agar and incubated
overnight at 35 ± 1°C in ambient air with 5% CO2. After
control of purity and presumptive identification by smell,
colony morphology and dependence of β-NAD and hae-
min, isolates were frozen at −70°C using Microbank vials
(Pro-Lab Diagnostics, Richmond Hill, Ontario, Canada).Resistant group
n=177
Study isolates 
n=196
Dead (n=5)
Impure (n=2)
No growth on MH-Fd (n=2)
Wrong speciese (n=4)
All isolates with reduced 
susceptibility to beta-lactams 
not explained by beta-lactamaseb
n=190
Isolates (o
wild type 
Selection
Inclusion
Exclusion
Figure 1 Study isolates. Flowchart showing selection and inclusion of ba
phenotypic susceptibility profiles (by gradient MIC, disk diffusion and beta-
following selection criteria were used: amoxicillin-clavulanate MIC ≥2 mg/L
cefaclor 30 μg zone <17 mm (all isolates); and ampicillin MIC ≥1 mg/L, ph
zone <16 mm (beta-lactamase negative isolates). The selection criteria wer
EUCAST (www.eucast.org/MIC_distributions) and zone diameter distributions
for susceptibility testing are included in the surveillance report [33]. cOne beta
from the isolates remaining after selection for the Resistant group. dMH-F, Mu
β-NAD for susceptibility testing of fastidious organisms (www.eucast.org). eH.Species identification was confirmed by outer membrane
protein P6 (ompP6) and 16S rRNA PCR using primers as
described previously [34] and probes designed for this
study (Table 2). Where this test was negative (n = 10), a
547 bp fragment of the 16S rRNA gene was sequenced at
GATC Biotech (Konstanz, Germany) to confirm species
identification.
Capsular serotyping was done by bexA PCR and
capsule type-specific PCRs for bexA positive isolates
as described previously [35], with modifications to the
HI-1, HI-2 and f3 primers. A new serotype e-specific
reverse primer and a bexA probe were designed for this
study (Table 2).
Susceptibility testing
MIC determination by microbroth dilution (HTM,
Oxoid Ltd, Basingstoke, UK) was carried out according
to CLSI guidelines [36], except that testing of penicillin-
beta-lactamase inhibitor combinations was performed
with fixed inhibitor concentrations [37]. Beta-lactam
agents tested were ampicillin, amoxicillin, piperacillin,Original 
populationa
n=808
Susceptible group
n=19
Denominator
Clinical data
n=795
Dead (n=3)
Remaining 
isolates
n=599
ne from each laboratory) with
susceptibility to beta-lactamsc
n=22
cterial isolates. aNORM 2007 surveillance population [33]. bAccording to
lactamase detection) as reported by the primary laboratories. The
, cefuroxime MIC ≥4 mg/L, cefotaxime MIC ≥0.12 mg/L and/or
enoxymethylpenicillin 10 μg zone <13 mm and/or ampicillin 2 μg
e constructed using epidemiological cut-off MIC values defined by
from the surveillance report [33]. Information about the methodologies
-lactamase negative isolate from each laboratory, randomly selected
eller-Hinton agar supplemented with defibrinated horse blood and
parainfluenzae (n = 3) and H. haemolyticus (n = 1).
Table 2 New and modified primers and probes used in this study
Name Function Target Sequences (5′ to 3′)a Original (reference)
bexAFb F-primer bexA CGTTTATRTGATGTTGATCCTGA HI-1 [35]
bexARb R-primer bexA TGTCCATATCTTCAAAATGGTG HI-2 [35]
bexAP Probe bexA FAM ATGCAAGYCGRGCTTTCATCCCTG-BHQ This study
Hinf_fR R-primer cap (serotype f) GGTACTATCAAGTCCAAATC f3 [35]
Hinf_eR2 R-primer cap (serotype e) CTAATTGTTCTTTCTGTCTA This study
ompP6P Probe ompP6 ACG TGG TAC ACC AGA ATA CAA CAT CGA This study
H16SP Probe 16S rRNA gene TCGCTCCACCTCGCAGCTTCGCT This study
TEMP Probe blaTEM CAG CTC CGG TTC CCA ACG ATC AAG This study
ROBP Probe blaROB TAG CGA CAA CAG CGC GAC CAA TTT G This study
aSites of modifications in bold.
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USA) and meropenem (Sequoia, Pangbourne, UK). For
beta-lactamase positive isolates, ampicillin, amoxicillin
and piperacillin MICs were determined in the presence of
sulbactam 4 mg/L (Sequoia), clavulanate 2 mg/L and tazo-
bactam 4 mg/L (Sigma-Aldrich), respectively. MICs were
within accepted ranges for H. influenzae ATCC 49247
(rPBP3) and H. influenzae ATCC 49766 (sPBP3), and within
the wild type range (www.eucast.org/MIC_distributions)
for H. influenzae ATCC 35056 (TEM-1 positive).
MICs were interpreted according to EUCAST clinical
breakpoints, except for piperacillin and piperacillin-tazo-
bactam where breakpoints are not defined [37]. Meningitis
breakpoints were used for susceptibility categorization of
meropenem to allow quantification of low-level resistance.
Data from this study are included in the EUCAST data-
base for MIC distributions of clinical isolates.
Resistance genotyping
PCR and sequencing of the transpeptidase domain of the
ftsI gene were performed as described previously [11].
DNA sequences were analysed using Lasergene software
(DNASTAR, Madison, WI, USA) and the sequences
(nucleotides 1010–1719) have been deposited in the
EMBL Nucleotide Sequence Database [EMBL:HG818627-
818822].
An UPGMA (unweighted pair group method with
arithmetic mean) phylogram of ftsI alleles from this and
a previous study [11] was constructed by distance methods
using ClustalW2 (www.ebi.ac.uk) and displayed using
TreeDyn software (www.phylogeny.fr) with H. parain-
fluenzae [EMBL:AB267856] as outgroup (Figure 2). Clus-
ters of closely related alleles were assigned Greek letters
(alpha – pi) with numbers denominating alleles within
each cluster.
According to PBP3 substitution patterns (Table 1), iso-
lates were categorized into resistance genotypes (Table 3).
Group II rPBP3 isolates and isolates lacking essential sub-
stitutions (denoted sPBP3) were assigned to PBP3 types(A – Q and z1 – z13, respectively) according to the pre-
viously established system [11], further developed in this
study.
The DNA and PBP3 sequences of H. influenzae Rd
KW20 [GenBank:U32793] were used as references
(alpha-0 and z0, respectively).
Isolates reported as beta-lactamase positive by the
primary laboratory and isolates with a phenotype suggest-
ing beta-lactamase production were examined by TEM-1
and ROB-1 PCR as described previously [38], with detec-
tion of PCR products by probes designed for this study
(Table 2).
Molecular strain characterization
MLST was performed by standard procedures with
sequencing of internal fragments of the seven house-
keeping genes adk, atpG, frdB, fucK, mdh, pgi and recA
[30]. Following registration of sequences at http://hae
mophilus.mlst.net for assignment of allele numbers and
STs, data were analysed using software available on the
website, with the construction of an UPGMA dendro-
gram based on the pairwise differences in allelic profiles
(Figure 3), and division of STs into clonal complexes (CC)
using eBURSTv3. The criterion for assignment to a CC
(named according to the predicted founder) was sequence
identity with another member of the complex at at least
six loci [31].
STs were assigned to phylogenetic groups (here denoted
phylogroups) according to previously performed max-
imum parsimony analysis of all STs in the MLST database
[32]. More recent STs, not encompassed by the parsi-
mony analysis, were indirectly assigned to phylogroups if
they belonged to CCs encompassing STs with known
phylogroup.
PFGE of the 177 isolates in the R-group was carried
out as described previously [11,38]. A dendrogram of
band patterns, with 46 isolates from our previous study
included [11], was constructed using GelCompare II
software (Applied Maths, Sint-Martens-Latem, Belgium),
Figure 2 (See legend on next page.)
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Figure 2 ftsI phylogram. UPGMA phylogram of ftsI DNA sequences (transpeptidase domain, nucleotides 1010–1719) in the current (n = 196) and
previous study (n = 46) [11]. The outgroup (Hpar) is H. parainfluenzae [EMBL:AB267856] and the reference sequence (z0) is H. influenzae Rd KW20
[GenBank:U32793]. The H. influenzae reference strains ATCC 49247 and ATCC 49766 are also included. The scale is DNA sequence divergence
(0.05 = 5% divergence). Labels indicate ftsI alleles, PBP3 types and number of isolates with the particular allele in the previous and current study,
respectively. The reference cluster alpha (green) and the alleles encoding PBP3 types A, B and D (red) are highlighted.
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rithm (Figure 4). Clusters of related or possibly related
isolates were identified by comparison of band patterns
[39] and numbered according to the system established
previously [11].
Statistics
Multivariate regression analysis and Fisher’s exact test
was performed using Predictive Analytics Software (PASW)
Statistics version 17.0 (IBM Corporation, US).
Ethics
The bacterial isolates and patient information used in
this study were collected as part of the Norwegian Sur-
veillance Programme for Antimicrobial Resistance (NORM).
The NORM programme is warranted in Norwegian law
(http://lovdata.no, FOR-2003-11-14-1353) and no further
ethical approval was required for the use of isolates and
data in this study.
Results
Resistance genotypes
In the R-group (n = 177), 116 isolates (66%) had essential
PBP3 substitutions and were categorized as rPBP3. The
remaining 61 isolates in the R-group, and all 19 isolates
in the S-group, lacked essential substitutions and were
categorized as sPBP3 (Table 4).
Most rPBP3 isolates were group II (111/116, 96%),
including seven TEM-1 positive isolates, but one group
III and two group III-like high-rPBP3 isolates were also
identified (Table 3). The rPBP3 prevalence in the original
population was thus 15% (116/795) and the prevalence
of combined rPBP3 and TEM-1 was 0.9% (7/795).
Eighteen PBP3 substitution patterns were present in
rPBP3 isolates, with PBP3 types A, B and D accounting
for 72% (84/116) and PBP3 type A alone accounting for
41% (48/116). The N526K substitution was encoded by
the DNA triplets AAA and AAG in 54% (61/112) and
46% (51/112) of the cases, respectively.
Analysis of the 49 ftsI alleles in the current study iden-
tified 14 clusters (Figure 2). PBP3 types A, B and D were
confined to distinct clusters (lambda, zeta and omicron),
all highly divergent from the reference sequence. Type A
was encoded by three closely related alleles (cluster
lambda) whereas types B (zeta) and D (omicron) showed
no allelic diversity. Several clusters encompassed more
than one PBP3 type, but only type J appeared in morethan one cluster (eta and delta). The lambda-1 and zeta
alleles, encoding PBP3 types A and B, respectively, were
highly prevalent in both sampling periods.
Serotypes and phylogeny
Except for two serotype f (Hif ) ear and respiratory tract
isolates, all study isolates were nontypeable.
The 196 isolates represented 70 STs; hereunder 15
novel (ST1190 through ST1204, represented by one iso-
late each) (Figure 3). Eight STs had >5 representatives and
accounted for 54% (105/196) of the isolates (Table 5). By
eBURST analysis, the STs were grouped into 39 clonal
complexes (CC) and three singletons.
Direct assessment of phylogroup was possible for 32
STs (accounting for 129 isolates) and indirect assignment
was possible for 30 STs (55 isolates). Eight STs (12
isolates) could not be assigned to a phylogroup. Ten out
of 14 recognized phylogroups [32] were represented, and
69% of the isolates belonged to Clade 13 (n = 59), eBURST
group 2 (n = 50) and Clade 9 (n = 26). The two Hif isolates
(sPBP3, ST124) were in Clade 2.
The S-group was more diverse than the R-group and
differed phylogenetically: fifteen STs were represented
among 19 S-group isolates, with only one, ST159, being
among the eight most frequent STs overall (Table 5).
Two major R-group phylogroups (eBURST group 2 and
Clade 8) were absent from the S-group.
Eight PFGE clusters of >5 isolates were identified, with
Dice coefficients of clustering between 71% and 76%
(Figure 4). PFGE clusters corresponded well to CCs,
occasionally with a higher or lower resolution level.
Additionally, two clusters (6B and 12) suggested genetic
relationship (by three band difference) between isolates
assigned to phylogroups (eBURST group 2 and Clade 13,
respectively) and isolates with no phylogroup assignment,
probably reflecting distant phylogenetic relationship not
detected by the parsimony analysis.
Phylogeny and resistance genotypes
The 116 rPBP3 and 80 sPBP3 isolates were distributed
on 32 and 44 STs, respectively. Six of the 70 STs in this
study (ST12, ST57, ST155, ST159, ST411 and ST422)
included both categories. Most rPBP3 isolates (102/116,
88%) belonged to five phylogroups (rPBP3 proportions
in brackets): eBURST group 2 (45/50, 90%); Clade 13
(28/59, 47%); Clade 9 (22/26, 85%); Clade 8 (5/8, 63%)
or Clade 10 (2/4, 50%). The remaining 14 rPBP3 isolates
Table 3 Resistance genotypes, PBP3 types and PBP3 substitutions
Resistance
genotypesa
PBP3
typesb
nc Sgd Blae PBP3 substitutionsf
D S A M S P A I G A V R N A T V D A N
350 357 368 377 385 392 437 449 490 502 511 517 526 530 532 547 551 554 569
High-rPBP3
Group III - 1 N N T T Kg I S
Group III-like - 2 N N I T H S I
Low-rPBP3
Group II A 48 1 N I V Kh I S
B 19 5 V Kg I S
C 5 N I E Kh I S
D 17 N E Kg S
F 1 Kg
H 6 V Kh
I 4 N S V Kg I S
J 3 N T Kg I S
K 2 T T Kg
L 1 N E Kg I Di S
M 1 N V Kh I S
N 1 1 N S V Kg I S
O 1 T Kg I S
P 1 T Kg I
Q 1 E V Kh I S
Group I - 2 H I T
sPBP3 z0 51 15 6
z4 9 1 N I S
z1 7 3 2 I
z6 3 I S
z7 3 I T S
z5 1 1 S
z8 1 N T I S
z9 1 N I
z10 1 I Ai
z11 1 A I
z12 1 Si
z13 1 T
aSee Table 1.
bPBP3 types according to Skaare et al. [11] (types A – G) and this study (types H – Q and z0 – z13). ‘-‘, not designated.
cn, No. of study isolates.
dSg, No. of isolates from the Susceptible group included in n.
eBla, No. of beta-lactamase positive isolates (all TEM-1) included in n.
fAmino acid substitutions in PBP3 (transpeptidase domain, 338–573) with the amino acid sequence of H. influenzae Rd KW20 [GenBank:U32793] as reference (z0).
Essential substitutions in bold.
gN526K encoded by the DNA triplet AAG.
hN526K encoded by the DNA triplet AAA.
iNovel substitution.
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and the single group III high-rPBP3 isolates were ST160
(no phylogroup) and ST1197 (Clade 13), respectively.
No isolates in Clade 1 (n = 5), Clade 2 (n = 4), Clade 6(n = 1), Clade 11 (n = 5) and Clade 12 (n = 2) were
rPBP3.
The ftsI alleles lambda-2, zeta and omicron, encod-
ing the three most frequent PBP3 types A, B and D,
Figure 3 (See legend on next page.)
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Figure 3 MLST dendrogram. The correlation between phylogenetic groups (MLST and PFGE) and resistance genotypes. UPGMA dendrogram of
STs based on pair-wise differences in allelic profiles of the 196 study isolates with additional information about CCs, phylogroups, PFGE clusters,
ftsI alleles, PBP3 types, PBP3 groups, beta-lactamase and study groups. The colour scale indicates relative frequencies of various alternatives within
each of the columns 1–6. eB gr2, eBURST group 2; Mis, miscellaneous; Sg, singletons; Ng, no phylogroup; S-group, Susceptible group; R-group,
Resistant group.
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by ST367 (eBURST group 2), ST396 (Clade 9) and ST201
(Clade 13) (Figure 3). In addition, PBP3 type A encoded
by the slightly different allele lambda-1 was present in
ST14, a triple locus variant of ST367 (both STs belong to
eBURST group 2). These four strains (defined by combi-
nations of STs and ftsI alleles) accounted for 61% (71/116)
of the rPBP3 isolates in the current study.
Two strains frequently occurring in this study (ST14
with PBP3 type A and ST396 with PBP3 type B) had
PFGE band patterns and ftsI alleles identical to strains in
the two most prevalent resistant clones three years earlier
(PFGE clusters 1 and 2, respectively) (Figure 4) [11].
Apart from ST367, PBP3 type A encoded by lambda-2
was present in the following unrelated STs: ST57 (Clade 8),
ST85 (Clade 9) and ST12 (no phylogroup). Similarly, the
ftsI allele gamma, encoding PBP3 type H, was present in
ST12 (no phylogroup) as well as the unrelated ST411 and
ST422 (Clade 10). Conversely, seven STs hosted more than
one PBP3 type. Notably, the six ST57 isolates carried four
highly divergent rPBP3 types (A, K, L and N) and the
reference sequence (z0).
Three ST57 isolates were TEM-1 positive but only one
isolate had both TEM-1 and rPBP3. Most isolates with
both resistance mechanisms (5/7, 71%) were ST396.
Clinical characteristics
Clinical information for the 196 study isolates and the
599 remaining isolates in the original population is
summarized in Table 4. For the study isolates, median
age and age range of the patients were 5 (0 – 86) yrs with
a male/female ratio of 1.0. The corresponding numbers in
the original population were 5 (0 – 97) and 1.0.
Multivariate regression analysis of isolates with known
hospitalization status (766/795, 96%) showed that in-
creasing age (OR = 1.3, p < 0.001) and male gender
(OR = 1.8, p = 0.001) were significant independent risk
factors for hospitalization. With adjustment for age,
gender and beta-lactamase production, there was a
borderline significant association between rPBP3 and
hospitalization (OR = 1.6, p = 0.053). Similarly, multi-
variate analysis of isolates with known site of isolation
(768/795, 97%) showed a significant association between
rPBP3 and eye infection (OR = 2.1, p = 0.003) but no asso-
ciation with other localizations. Information about STs
was available for study isolates only and thus not included
in the regression analysis.The eight most prevalent STs were highly diverse with
respect to resistance genotypes and clinical characteris-
tics (Table 5). There was no correlation between rPBP3
proportions and hospitalization rates in the various STs.
Three STs, two of which consisting entirely of rPBP3
isolates (ST396 and ST201) were significantly associated
with eye infection (p < 0.05). ST396 was also significantly
associated with the age group 0–3 yrs (p = 0.004).
Beta-lactam susceptibility
Median MICs (MIC50) were generally ≥2 dilution steps
higher in group II rPBP3 isolates than in sPBP3 isolates
(Table 6). The single group III high-rPBP3 isolate had
MICs ≥2 steps higher than MIC50 in group II isolates.
MIC50 for cefotaxime differed slightly between isolates
with PBP3 types A (0.03 mg/L), B (0.016 mg/L) and D
(0.06 mg/L). There were otherwise no significant differ-
ences (within ±1 dilution step) between MIC50 in various
PBP3 types, nor between sPBP3 isolates in the two study
groups.
The majority of group II isolates had MICs above the
S-breakpoints for ampicillin, amoxicillin and cefuroxime.
Significant proportions were resistant to cefotaxime
(7/111, 6%) and non-susceptible to meropenem (22/111,
20%), with representatives from all four major rPBP3
strains. Notably, 12% (13/111) of group II isolates were
categorized as susceptible to all agents, whereas 24%
(19/80) of sPBP3 isolates were non-susceptible to ≥1
beta-lactam, most commonly intermediately susceptible
to cefuroxime (n = 10). No association with ST or phylo-
group was observed.
The prevalences of clinical PBP3-mediated resistance
to ampicillin and cefotaxime and non-susceptibility to
meropenem in the original population (n = 795) were
9%, 1.3% and 2.9%, respectively.
Discussion
Resistance epidemiology
We found a 15% prevalence of rPBP3 in a nationwide
collection of 795 eye, ear and respiratory isolates of
H. influenzae in Norway. The prevalence of clinical
resistance to ampicillin due to rPBP3 was 9%, compared
to 2.5% in a similar study three years earlier [11]. Despite
methodological differences between the two studies, we
conclude with a significant increase from 2004 to 2007.
National phenotypic surveillance data indicate a further
increase to 17% rPBP3 in respiratory isolates in 2011 [40]
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Figure 4 (See legend on next page.)
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Figure 4 PFGE dendrogram. The correlation between phylogenetic groups (PFGE and MLST) and resistance genotypes. UPGMA dendrogram of
band patterns for the 177 isolates in the Resistant group and 46 isolates from a previous study [11]. Clusters of related or possibly related isolates
by analysis of band patterns and Dice coefficient of similarity are indicated by colours. Horizontal lines separate different band patterns.
Additional information about STs, CCs, phylogroups, ftsI alleles, PBP3 types, PBP3 groups and strain origin is provided. The colour scale (similar to
Figure 3) indicates relative frequencies of various alternatives within each of the columns 1–6. eB gr2, eBURST group 2; Mis, miscellaneous;
Sg, singletons; Ng, no phylogroup.
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http://www.biomedcentral.com/1471-2180/14/131and a prevalence at 15% rPBP3 in invasive isolates in 2012
(n = 73, 77% nontypeable) [41], consistent with obser-
vations in other European countries and in Canada
[2,4,12,14].
As expected, group II low-level resistant isolates pre-
dominated. Notably, group III high-rPBP3 was identified
for the first time in Northern Europe. The genotypic
distinction between low-level and high-level beta-lactam
resistance is clinically relevant: As resistance to cefo-
taxime is mainly seen in high-rPBP3 [6], cefotaxime is
suitable for empiric treatment of severe disease only in
regions where high-rPBP3 is rare. However, 6% of group
II isolates in the present study were resistant to cefotax-
ime and 20% were non- susceptible to meropenem in
case of meningitis. These observations underline the im-
portance of confirming susceptibility to beta-lactams in
severe infections such as meningitis and septicemia.
When the prevalence of low-rPBP3 in Japanese re-
spiratory isolates reached 17% in the mid 1990s, group
III isolates increased from zero to 29% in six years [13].
This was followed by a rapid increase in group III
isolates in meningitis (predominantly Hib) from zero to
70% [15]. A recent report revealed a shift from low-level
to high-level resistance in respiratory tract isolates in
South Korea during the last decade, with an increase in
the prevalence of group III isolates from 1% to 21% in
five years [16,22].
A similar development in other parts of the world would
seriously compromise current empiric antibiotic therapy
in severe infections. So far, single group III isolates haveTable 4 Frequencies of beta-lactam resistance and clinical char
rPBP3c Blad
Groups of isolatesb n n % n %
Ey
Resistant group 177 116 66 16 9 2
Susceptible group 19 0 0 0 0 2
Remaining isolates 599 0f 0f 60g 10g 1
Original population 795h 116 15 76 10 2
aNORM 2007 surveillance population [33], consisting of consecutive routine isolates
bSee text and Figure 1 for definition of the study groups (Resistant group and Susc
cPBP3-mediated resistance (see Table 1).
dBeta-lactamase positive.
eProportions of patients hospitalized at the time of sampling.
fAssuming that all rPBP3 isolates were selected for the Resistant group.
gAs reported by the primary laboratories.
hThirteen isolates were selected for the Resistant group but excluded for various rebeen reported from France [14] and Canada [3]
whereas group III-like isolates are slightly more fre-
quent [9,14,18,20,21,24]. Clusters of group III and
group III-like high-level resistant isolates were
recently observed in Norway (Skaare et al., manuscript in
preparation).
The current epidemiologic situation in Europe and
Canada, with a gradually increase in low-rPBP3 and
sporadic reports of high-rPBP3 isolates, strongly resem-
bles the situation in Japan and South Korea prior to the
shifts in resistance genotypes. Continuous monitoring of
susceptibility to cefotaxime and meropenem is necessary
to ensure safe empiric treatment.
Molecular epidemiology
By comparing the study isolates with isolates from a com-
parable population collected in 2004 [11], we were able to
study the clonal dynamics of PBP3-mediated resistance.
The increasing prevalence of rPBP3 in Norway is due to
expansion of a few clones. Four STs with characteristic
ftsI alleles accounted for 61% of the rPBP3 isolates in
the present study. Two of these strains were the main con-
tributors to PBP3-mediated resistance in Norway three
years earlier [11]. Interestingly, the replacement of ST14
by ST367 as the most prevalent rPBP3 strain did not cause
a shift in PBP3 type nor phylogroup, as both STs carried
PBP3 type A and belong to eBURST group 2.
We have previously suggested the existence of one or
more widely disseminated rPBP3 clones [11]. This is sup-
ported by later reports of PBP3 type A and compatibleacteristics in study groups and in the original populationa
Proportions (%) of isolates and patients
Anatomical sites Age groups Hospitalizede
e Ear Respiratory 0-3 ≥50
8 10 58 44 24 33
1 32 42 68 5 11
9 15 63 41 22 23
1 14 62 43 22 25
from patients with eye, ear and respiratory tract infections.
eptible group).
asons (see Figure 1).
Table 5 Frequencies of beta-lactam resistance and clinical characteristics of study isolates according to STs
rPBP3a Blab Proportions (%) of isolates and patientsc
STs n n % n % Anatomical sites Age groups Hospitalizedd
Eye Ear Respiratory 0-3 ≥50
ST367 29 29 100 0 0 17 17 59 28 34 28
ST396 16 16 100 5 31 56e 6 38 81f 13 38
ST201 15 15 100 0 0 53e 0 47 47 27 47
ST159 12 1 8 0 0 8 8 75 33 42 50
ST14 11 11 100 1 9 18 0 73 64 9 55
ST12 8 7 88 0 0 50 13 38 38 13 25
ST395 8 0 0 0 0 63e 0 25 63 25 0
ST57 6 4 67 3 50 33 17 50 83 17 33
Other STs 91 33 36 7 8 19 16 60 58 19 25
All STs 196 116 59 16 8 27 12 56 46 22 31
aPBP3-mediated resistance (see Table 1).
bBeta-lactamase positive (all TEM-1).
cProportions for each ST were compared with the proportions for other STs (e.g. ST396 versus non-ST396) using Fisher’s exact test. Characteristics significantly
more prevalent in particular STs are indicated (bold).
dProportions of patients hospitalized at the time of sampling.
ep < 0.05.
fp = 0.004.
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http://www.biomedcentral.com/1471-2180/14/131substitution patterns (identical to PBP3 type A as far
as comparison is possible) being common in Europe
[4,18,23-25], Canada [3,12], Australia [20] and South Korea
[16,22], and by the present study.
PBP3 type A is frequently linked to ST14 and ST367
in the limited number of previous reports on the molecular
epidemiology of rPBP3. Studies on invasive H. influenzae
in Canada in the periods 2000–2006 [2,12,42] and 2008–
2009 [3] revealed an increasing prevalence of rPBP3 inTable 6 Beta-lactam susceptibility according to PBP3 resistan
Study groupsa Resistance genotypesb n
AMPc
Resistant group High-rPBP3 Group III 1 8/-
(0/100)
Group III-like 2 2/4
(0/100)
Low-rPBP3 Group II 111 2/4
(40/60)
Group I 2 0.5/1
(100/0)
sPBP3 60 0.25/0.5
(98/2)
Susceptible group sPBP3 19 0.12/0.5
(100/0)
aSee Figure 1.
bSee Table 1.
cMICs (microbroth dilution) and susceptibility categorization (S/R or S/I/R) according
(S≤/R>): Ampicillin (AMP), 1/1; amoxicillin (AMC), 2/2; cefuroxime (CXM), 1/2; cefotax
piperacillin and piperacillin-tazobactam are not set by EUCAST. Meningitis breakpoi
dFor beta-lactamase positive isolates, ampicillin, amoxicillin and piperacillin MICs we
and tazobactam (4 mg/L), respectively.NTHi, with PBP3 type A being common in both sampling
periods [3,12]. ST14 and ST367, respectively, were the
most common STs in NTHi from two different regions
and sampling periods [3,42]. PBP3 type A was by far the
most frequent substitution pattern in ST14 and also
appeared in some ST367 isolates (R. Tsang, personal
communication).
Furthermore, a study on invasive H. influenzae in
Sweden [4] identified a cluster of seven NTHi isolates ofce genotypes
MIC50/MIC90 (mg/L) and susceptibility categorization (%)
c
AMCc PIPc CXM CTX MEM
16/- 0.06/- >16/- 0.25/- 1/-
(0/100) (0/0/100) (0/100) (0/100/0)
8/16 0.06/0.12 >16/>16 0.06/0.12 0.03/0.03
(0/100) (0/0/100) (100/0) (100/0/0)
4/8 0.03/0.06 8/8 0.03/0.12 0.12/0.5
(45/55) (33/11/56) (94/6) (80/20/0)
0.25/1 0.03/0.06 0.5/16 0.06/0.25 0.016/0.06
(100/0) (50/0/50) (50/50) (100/0/0)
0.5/2 0.004/0.03 1/8 0.008/0.06 0.03/0.12
(98/2) (74/13/13) (98/2) (100/0/0)
0.5/2 0.004/0.06 0.5/8 0.004/0.03 0.03/0.12
(95/5) (79/11/11) (100/0) (100/0/0)
to EUCAST clinical breakpoints [37]. The following breakpoints were used
ime (CTX), 0.12/0.12; meropenem (MEM), 0.25/1. Clinical breakpoints for
nts were used for categorization of meropenem.
re determined in combination with sulbactam (4 mg/L), clavulanate (2 mg/L)
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PBP3 type A and collected in the period 2008–2010
(F. Resman, personal communication). Finally, in two
recently published Spanish studies, ST14 and/or ST367
isolates with substitution patterns compatible with PBP3
type A were reported in invasive disease (ST367, n = 2)
[24] and pneumonia (ST14, n = 2; ST367, n = 1) [25] in
the period 2000–2009.
The ftsI alleles encoding type A in this and our previ-
ous study [11] had high genetic similarity and alleles in
separate clusters rarely encoded identical PBP3 types.
Thus, despite the lack of cross-study comparison of ftsI
DNA sequences, the examples above indicate that clonal
distribution is a more likely explanation for the occur-
rence of PBP3 type A and compatible patterns in separate
studies from four continents [3,4,9,11,12,16,18,20,22-25]
than independent development of this substitution pattern
by convergence.
Importantly, an invasive high-level resistant rPBP3
isolate with the same combination of MLST allelic
profile (ST155) and PBP3 substitution pattern as the
two group III-like isolates in the present study was
recently reported from Spain [24]. A single-locus variant
(ST1118) with an identical substitution pattern was also
reported.
These observations are notable and support the need
of global surveillance initiatives. We here show that
combining MLST and PBP3 typing provides a tool for
cross-study identification of rPBP3 strains and clones.
The previously suggested system for subgrouping of
group II isolates [38] does not separate PBP3 types [11,16]
and is unsuitable for this purpose.
Preferably, MLST should be combined with ftsI DNA
sequencing. The ftsI gene is nearly 200 kb from its nearest
MLST neighbor (mdh) and distortion of the MLST results
due to linkage is thus very unlikely. With recent techno-
logical development reducing both costs and analysis time
of whole-genome sequencing, and smaller bench-top se-
quencers becoming readily available, MLST-ftsI typing will
probably be possible to perform for surveillance purposes
in the near future.
We are aware of a number of previous studies
where MLST and ftsI sequencing was performed
[3,4,12,23-25,43-45]. To our knowledge, four reports
have linked MLST data and PBP3 substitution pat-
terns: one presented the allelic profiles of 83 group
III respiratory isolates from Japan [43]; another pre-
sented the substitution pattern of a single group II
ST368 NTHi isolate causing meningitis in Italy [44];
and two most recent publications presented the sub-
stitution patterns and STs of 95 respiratory [25] and 18
invasive isolates [24] from Spain. However, the present
study is to our knowledge the first to connect STs to
ftsI alleles.PFGE is highly discriminative and generally considered
suited for assessment of relatedness between epidemio-
logically connected isolates, particularly in populations
with high recombination rates such as NTHi [39,46]. In
this study, PFGE clusters correlated well to MLST clonal
complexes. Band patterns were stable over time and also
traced phylogenetic relationship not detected by MLST
and parsimony analysis. Combining MLST and PFGE for
typing of NTHi may thus increase both sensitivity and
resolution of clone detection.
Development of resistance
As discussed above, clonal expansion is important for
the spread of rPBP3. However, the PBP3 type A-encoding,
highly divergent ftsI allele lambda-2 was distributed
among several unrelated STs. Similar observations are
reported previously but only in studies using PFGE for
strain characterization [11,26]. Exchange of complete
alleles by HGT seems the most likely explanation, and
has been demonstrated in vitro [26]. The mechanisms
for HGT of ftsI sequences in H. influenzae are not
completely resolved but involvement of classical trans-
formation and homologous recombination has been sug-
gested [26,47].
Transformational competence varies extensively between
H. influenzae strains [48]. This implies that the ability to
acquire mutant ftsI alleles encoding rPBP3 will vary corres-
pondingly, which may explain the differences in ST and
phylogroup distribution between rPBP3 and sPBP3 isolates.
It has been suggested that phylogroups are maintained by
restriction barriers, preventing recombination between
isolates of different heritage [32]. This is challenged by the
distribution of lambda-2 to several phylogroups. A simple
explanation may be that restriction barriers prevent
recombination between some phylogroups and allow
recombination between others.
Recent studies applying whole-genome sequencing have
revealed that transformation in competent strains of
H. influenzae is more extensive than previously recog-
nized [49] and that transformational exchange may cause
allelic variation involving complete genes between strains
of identical STs [50]. However, transfer of complete
ftsI alleles is probably less common than exchange of
shorter sequences, causing mosaicism [26,28]. Prelim-
inary multiple sequence alignment analysis of ftsI se-
quences in this study indicated intrageneic recombination
(data not shown).
PBP3-mediated resistance and virulence
The association between rPBP3 and virulence is poorly
described. One experimental study reported increased
ability of a group III NTHi strain to invade bronchial epi-
thelial cells, and the authors hypothesized that rPBP3 may
enhance virulence by acting as an adhesion molecule [51].
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cluded with no difference in pathogenicity between rPBP3
and sPBP3, but an association between rPBP3 and under-
lying respiratory disease was observed [17]. Molecular
strain characterization was not performed in any of the
two studies.
In the present study, regression analysis (without
adjustment for ST) suggested that rPBP3 is associated
with increased risk of eye infection and hospitalization.
However, ST-specific analysis indicated that pathogen-
icity is correlated with STs rather than with resistance
genotypes. For instance, ST395, ST396 and ST201 were
significantly associated with eye infections but only the
two latter STs were associated with PBP3-mediated
resistance.
Irrespective of resistance genotypes, a number of STs
in this study had clinical characteristics recognizable
from previous reports: ST159 was predominantly isolated
from the respiratory tract of hospitalized elderly patients,
consistent with ST159 being adapted to infection in
chronic obstructive pulmonary disease (COPD) [52]; and
the high proportion of ST57 in children is consistent with
a previously reported association with acute otitis media
(AOM) [53]. Finally, the high hospitalization rate of
patients with ST14-PBP3 type A corresponds well with
the potential of this strain to cause pneumonia [25] and
invasive disease [3,4,42].
These observations are in accordance with a recent
population study suggesting association between popula-
tion structure and disease [53]. In conclusion, the associ-
ation between rPBP3 and pathogenicity suggested by the
regression analysis most likely reflects that some of the
most frequently occurring rPBP3 strains in this study also
possessed strain-associated virulence properties. Identifi-
cation of virulence determinants is beyond the scope of
this study. However, our observations underline that
studies on the correlation between resistance genotypes
and pathogenicity should include molecular strain cha-
racterization. Accordingly, the previously reported asso-
ciation between PBP3-mediated resistance and clinical
characteristics [17,51] may be spurious.
Conclusions
The prevalence of rPBP3 in H. influenzae is increasing
worldwide, and high-level resistant strains are emerging
in new geographic regions.
In this study of eye, ear and respiratory isolates in
Norway, the rPBP3 prevalence was 15%, with four strains
accounting for 61% of the resistant isolates. Group II low-
rPBP3 isolates predominated, and significant proportions
of isolates were non-susceptible to cefotaxime and mero-
penem. Group III high-rPBP3 was identified for the first
time in Northern Europe.The results support a role of horizontal gene transfer
in the emergence of rPBP3 and indicate phylogeny
restricted transformation. Comparative analysis with
data from previous studies indicates wide dissemination
of clonally related rPBP3 strains. Notably, two strains
highly prevalent in Norway (ST14 and ST367 with PBP3
type A) are common in invasive disease in Europe
and Canada.
Continuous monitoring of beta-lactam susceptibility is
necessary to ensure safe empiric therapy in severe
disease and to detect a future shift from low-level to
high-level resistance. The need of a global system for
molecular surveillance of rPBP3 strains is underlined.
The novel approach of combining MLST and ftsI/PBP3
typing is a powerful tool for this purpose.
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